WTX-124
Advanced or Metastatic Solid Tumors
Phase 1/1bActive
Key Facts
Indication
Advanced or Metastatic Solid Tumors
Phase
Phase 1/1b
Status
Active
Company
About Werewolf Therapeutics
Werewolf Therapeutics is on a mission to transform cancer treatment by developing safer, more effective immunotherapies. Its core innovation is the PREDATOR™ protein engineering platform, which creates conditionally activated cytokine prodrugs (INDUKINE™ molecules) designed to activate only in the tumor microenvironment. The company has successfully advanced two lead candidates, WTX-124 (IL-2) and WTX-330 (IL-12), into Phase 1/1b clinical trials for advanced solid tumors and has initiated a strategic alternatives process to maximize shareholder value. Werewolf's strategy centers on leveraging its platform to overcome the historical limitations of potent immunomodulators.
View full company profileTherapeutic Areas
Other Advanced or Metastatic Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| AN4005 | Adlai Nortye | Phase 1 |
| WTX-330 | Werewolf Therapeutics | Phase 1 |